Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

NCT02983799 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Interventions

DRUG: OLAPARIB

Sponsor

AstraZeneca